Abstract | OBJECTIVE: METHODS: We retrospectively evaluated patients receiving both chemotherapy and pegfilgrastim from June 1, 2006 to August 31, 2007 for a gynecologic malignancy. Abstracted data included patient demographics, pathology, blood counts, toxicity, and chemotherapy. After administration of chemotherapy, all patients either received 6 mg of pegfilgrastim subcutaneously on day 1 or day 2. RESULTS: 1226 administrations of pegfilgrastim in 230 patients were identified. 490 administrations of pegfilgrastim were given on day 1 compared to 736 on day 2. 70% of patients had ovarian cancer with a median age of 64 years (range 15-88). 79% of patients had stage III, IV, or recurrent disease and 67% were undergoing primary chemotherapy. The most common chemotherapy was docetaxel/ carboplatin (53%) followed by paclitaxel/ carboplatin (19%). The mean absolute neutrophil count (ANC) nadir was 4810/mm(3) in the day 1 cohort compared to 4212/mm(3) in the day 2 cohort (p=.004). The incidence of Grade 3/4 neutropenia was similar in both groups (4.9% in day 1 vs. 5.7% in day 2; p=.63). Grade 3/4 febrile neutropenia was uncommon in both cohorts (0 episodes vs. 3 episodes; p=.41). Treatment delays were similar in both cohorts (5.9% vs. 7.5%; p=.35). Dose modifications were also similar in both cohorts (2.8% vs. 5.3%; p=.06). CONCLUSION:
|
Authors | Jenny M Whitworth, Kellie S Matthews, Kimberly A Shipman, T Michael Numnum, James E Kendrick, Larry C Kilgore, J Michael Straughn Jr |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 112
Issue 3
Pg. 601-4
(Mar 2009)
ISSN: 1095-6859 [Electronic] United States |
PMID | 19110303
(Publication Type: Journal Article)
|
Chemical References |
- Recombinant Proteins
- Taxoids
- Granulocyte Colony-Stimulating Factor
- Docetaxel
- pegfilgrastim
- Polyethylene Glycols
- Carboplatin
- Paclitaxel
- Filgrastim
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Carboplatin
(administration & dosage, adverse effects)
- Docetaxel
- Drug Administration Schedule
- Female
- Filgrastim
- Genital Neoplasms, Female
(blood, drug therapy)
- Granulocyte Colony-Stimulating Factor
(administration & dosage)
- Humans
- Middle Aged
- Neutropenia
(chemically induced, prevention & control)
- Paclitaxel
(administration & dosage, adverse effects)
- Polyethylene Glycols
- Recombinant Proteins
- Retrospective Studies
- Taxoids
(administration & dosage, adverse effects)
- Young Adult
|